Orthopaedic Implant Company receives FDA clearance for high-value dorsal spanning plate
Click Here to Manage Email Alerts
The Orthopaedic Implant Company has announced FDA clearance and commercial launch of its high-value dorsal spanning plate, adding to the trauma implant portfolio of the company, according to a press release.
The high-value dorsal spanning plate can be used in conjunction with the DRPx distal radius plating system from the company to improve outcomes for patients with wrist fractures, according to the release.
“If we want value-based care to work, then implant companies have to play their part,” Itai Nemovicher, president and CEO of Orthopaedic Implant Company, said in the release. “The reality right now is that [ASCs] are only being reimbursed at 53% the rate we’re seeing with hospitals performing the exact same procedures, so this is where we can make a huge difference for ASCs. Adding the dorsal spanning plate to our DRPx system provides surgeons and facilities with the chance to substantially increase value on a high-volume procedure, streamline operations and get the exact same clinical results they’re getting with more expensive implant systems,” Nemovicher added.
Read more about
Click Here to Manage Email Alerts